Evaluation of Sloan-Charts for Assessment of Disease Progress in Multiple Sclerosis
Impairment of visual deficits, in particular contrast acuity and contrast impairment are frequent symptoms in MS. However, visual function is not appropriately covered by the standard tools for clinical assessment, namely, the EDSS and the MSFC.
The primary aim of this study is to investigate, whether in MS patients contrast acuity and sensitivity change over a period of two years.
Secondary aims are the correlation of visual contrast parameters with structural retinal changes and quality of life.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Evaluation of Low Contrast Sloan Visual Charts as Method for the Assessment of Disease Progression in Multiple Sclerosis|
- Visual Contrast Acuity [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- Structural and Functional Changes of Optic Pathway [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- Clinical Neurological Assessment [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- Quality of Life [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
- Contrast Sensitivity [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
|Study Start Date:||December 2009|
|Study Completion Date:||November 2013|
|Primary Completion Date:||November 2013 (Final data collection date for primary outcome measure)|
Multiple Sclerosis Patients
Patients with Clinically Isolated Syndrome or definite Multiple Sclerosis (either relapsing-remitting or secondary progressive)
Please refer to this study by its ClinicalTrials.gov identifier: NCT01272596
|NeuroCure Clinical Reserach Center, Charité Universitaetsmedizin|
|Berlin, Germany, 10117|
|Principal Investigator:||Jan M Dörr, MD||NeuroCure Clinical Research Center, Charité Universitaetsmedizin Berlin|